| 9.7205 -9.08 (-48.3%) | 11-11 09:41 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.1  |
1-year : | 41.83 |
| Resists | First : | 29.2 |
Second : | 35.81 |
| Pivot price | 23.94 |
|||
| Supports | First : | 18.5 | Second : | 15.39 |
| MAs | MA(5) : | 19.58 |
MA(20) : | 25.38 |
| MA(100) : | 34.92  |
MA(250) : | 24 |
|
| MACD | MACD : | -3.8 |
Signal : | -3.2 |
| %K %D | K(14,3) : | 1.8 |
D(3) : | 4.2 |
| RSI | RSI(14): 26.3 |
|||
| 52-week | High : | 65.8 | Low : | 1.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VOR ] has closed above bottom band by 12.6%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.86 - 19.97 | 19.97 - 20.07 |
| Low: | 18.48 - 18.62 | 18.62 - 18.75 |
| Close: | 18.6 - 18.8 | 18.8 - 18.99 |
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Tue, 11 Nov 2025
Can a trend reversal in Vor Biopharma Inc. lead to recovery - July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Tue, 11 Nov 2025
Vor Biopharma Inc. (VOR) Stock: Shares Surge as Company Launches $100 Million Offering - parameter.io
Tue, 11 Nov 2025
Vor Biopharma Prices $100 Million Common Stock Offering; Shares Down Pre-Bell - MarketScreener
Tue, 11 Nov 2025
Vor Biopharma (VOR) Launches $100M Public Offering Amid Stock Dr - GuruFocus
Tue, 11 Nov 2025
Vor Biopharma slumps 26%, prices $100M equity at $10 per share - MSN
Mon, 10 Nov 2025
Vor Bio prices $100 million public offering of common stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 28.1 (%) |
| Held by Institutions | 28.7 (%) |
| Shares Short | 1,240 (K) |
| Shares Short P.Month | 1,100 (K) |
| EPS | -273.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -239.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -121.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -48.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -150 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | -0.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|